Regional anesthetic SPG block-bilateral

Phase 1Small molecule

Regional anesthetic SPG block-bilateral is one of 47 small molecule programs targeting Aneurysm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AneurysmActive, not recruiting

AneurysmPhase 1

Active, not recruiting

Competition

Competitive Landscape

71 competitors in Aneurysm

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

2 2

Keppra

UCB

Approved

2 3

Tecfidera

Biogen

Approved

1 4

Xarelto

WWim Janssens

Approved

1 5

Effient

CCosette Pharmaceuticals, Inc.

Approved

1 6

Pletal

Otsuka

Approved

1 7

Bayer Aspirin

Bayer

Phase 3

5 8

Coumadin

Brilinta

1 10

Zocor

OOrganon and Co

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aneurysm1 trial

Efficacy of Percutaneous SPG Block in Aneurysmal SAH

Completed·MMayo Clinic·Phase 1·NCT04331938·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Regional anesthetic SPG block-bilateral. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Regional anesthetic SPG block-bilateral compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Regional anesthetic SPG block-bilateral. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMayo Clinic

Regional anesthetic SPG block-bilateral

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aneurysm1 trial

References

Drug Info

Quick Facts

Related News